Leukotuximab Biosimilar – Anti-GPL115 mAb – Research Grade from ProteoGenix; catalogue PX-TA2041; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Leukotuximab Biosimilar, also known as Anti-GPL115 mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Leukotuximab. This biosimilar is a promising new treatment option for various diseases, as it has shown to have similar structure, activity, and therapeutic potential as the original Leukotuximab antibody. In this article, we will discuss the structure, activity, and potential applications of Leukotuximab Biosimilar in detail.
Leukotuximab Biosimilar is a monoclonal antibody that specifically targets the glycoprotein 115 (GPL115). It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and belongs to the immunoglobulin G (IgG) class. It is produced through recombinant DNA technology, using mammalian cells as expression systems.
The structure of Leukotuximab Biosimilar is highly similar to that of the original Leukotuximab antibody, with only minor differences in the amino acid sequence. This similarity in structure allows for the biosimilar to have comparable activity and therapeutic effects as the original antibody.
Leukotuximab Biosimilar works by binding to GPL115, which is a cell surface glycoprotein that is overexpressed in various types of cancer cells. This binding inhibits the growth and survival of cancer cells, leading to their death. The antibody also has the ability to activate the immune system, specifically the complement system, which further enhances its anti-tumor activity.
Studies have shown that Leukotuximab Biosimilar has similar activity to the original Leukotuximab antibody in terms of binding affinity to GPL115 and inhibition of tumor growth. This has been demonstrated in preclinical studies as well as in clinical trials, where the biosimilar has shown promising results in treating various types of cancer, including breast, lung, and colon cancer.
Leukotuximab Biosimilar has the potential to be used as a therapeutic agent for various diseases, particularly cancer. Its ability to specifically target GPL115, which is overexpressed in many types of cancer, makes it a promising treatment option. Furthermore, its biosimilarity to the original Leukotuximab antibody allows for easier and faster approval by regulatory agencies, making it more accessible to patients.
In addition to its potential as a cancer treatment, Leukotuximab Biosimilar may also have applications in other diseases where GPL115 is involved. This includes autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, as well as inflammatory conditions like psoriasis and Crohn’s disease. Further research is needed to explore the full potential of this biosimilar in these diseases.
Leukotuximab Biosimilar, also known as Anti-GPL115 mAb, is a promising new treatment option for various diseases, particularly cancer. Its similar structure and activity to the original Leukotuximab antibody makes it a highly effective and safe therapeutic agent. With ongoing clinical trials and further research, Leukotuximab Biosimilar has the potential to improve the lives of many patients in need of effective treatments.
In summary, Leukotuximab Biosimilar is a monoclonal antibody that specifically targets GPL115 and has shown promising results in preclinical and clinical studies as a cancer treatment. Its biosimilarity to the original antibody allows for easier approval and potential applications in other diseases. With its potential to improve patient outcomes, Leukotuximab Biosimilar is a valuable addition to the arsenal of therapeutic antibodies.
ProteoGenix catalogue number PX-TA2041. For research use only.
Target: Leukotuximab Biosimilar – Anti-GPL115 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Leukotuximab Biosimilar – Anti-GPL115 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
